CNS Pharmaceuticals, Inc. (CNSP)


-0.06 (-2.75%)
Symbol CNSP
Price $2.12
Beta 1.132
Volume Avg. 0.07M
Market Cap 11.127M
Shares () -
52 Week Range 0.611-4.4
1y Target Est -
DCF Unlevered CNSP DCF ->
DCF Levered CNSP LDCF ->
ROE -615.75% Strong Sell
ROA -815.85% Strong Sell
Operating Margin -
Debt / Equity -2.41% Neutral
P/E -0.28 Neutral
P/B -5.09 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest CNSP news

Mr. John Michael Climaco Esq., J.D.
NASDAQ Capital Market

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.